For most of pharmaceutical history, the hard part was finding a molecule that worked. The GLP-1 class inverted that logic. The science arrived first — semaglutide and tirzepatide delivered weight-loss numbers clinicians had spent careers dreaming about — and then the factories could not keep up. For three years the drugs sat on shortage lists, compounding pharmacies filled the gap, and the binding constraint turned out to be neither biology nor regulation. It was the capacity to make the peptide.

That single fact is now reshaping the manufacturing map of Asia-Pacific. Strip away the branding and the weight-loss headlines and the GLP-1 phenomenon is, at root, a peptide-synthesis and sterile-injectable problem — thirty-odd amino acids assembled, purified, formulated and filled, at volumes the peptide industry has never before been asked to produce. Whoever can build that capability at scale, at cost and at quality captures a slice of a market that most forecasters put north of US$150 billion by 2030. And across the region, from Hyderabad to Yangzhou to Sejong, a capital race is on to do exactly that.

The prize is real. So is the risk. Because the same demand curve that justifies a nine-figure reactor build-out is also the one most exposed to a patent cliff that has already begun, to oral competitors that need no peptide reactors at all, and to a future wave of biosimilars and compounded copies. APAC's peptide bet is a wager on durability — that the demand holds long enough, and in the right form, to pay back the concrete.

THE DEMAND SIGNAL

Start with the scale of what has to be manufactured. GLP-1 receptor agonists are complex peptides, typically 29 to 39 amino acids long, and the workhorse of their production is solid-phase peptide synthesis (SPPS) — a stepwise assembly on a resin support, run through repeated coupling and deprotection cycles before the chain is cleaved, purified by preparative chromatography and dried. It is chemistry that peptide houses have run for decades, but never at this tonnage. Commercial GLP-1 demand can reach tens or hundreds of kilograms of active ingredient a year per product, and in aggregate the class is pushing peptide manufacturing toward metric-ton output for the first time. The processes are also punishingly solvent-hungry: GLP-1 synthesis can consume many times the solvent volume of a conventional peptide campaign, turning capacity into a question of environmental permitting and waste handling as much as reactor litres.

The numbers that matter are the kilograms. In a widely-circulated 2026 analysis, Goldman Sachs modelled global peptide-API demand at roughly 99,000 kilograms a year by 2030 to serve the GLP-1 class — a figure that reframes the entire conversation from marketing spend to industrial chemistry. The bank put US GLP-1 sales alone at around US$66 billion by 2030, split roughly evenly between orals and injectables, requiring on the order of 35,000 kilograms of peptide API by 2030 and 57,000 kilograms by 2035. The market outside the United States and China — the ex-US, ex-China anti-obesity opportunity that APAC exporters are best positioned to serve — was pegged near US$43 billion by 2030, calling for roughly 32,000 kilograms of API by 2030 and 48,000 kilograms by 2035.

Behind those tonnages sits a fork in the road that defines who can compete and on what economics. There are two manufacturing routes to a GLP-1 peptide. The first is fermentation, or recombinant expression — the approach the originator uses for semaglutide and liraglutide; it is capital-heavy and slow to build but delivers the lowest unit cost at scale, part of why the branded incumbent remains the cheapest producer of its own molecule. The second is synthetic SPPS — the route for tirzepatide, retatrutide and the majority of the generic field. SPPS carries far lower upfront capex than fermentation, a decisive advantage for a generics entrant or a CDMO trying to move fast, but it is harder to scale, and yields, utilisation and purity all become the difference between a profitable line and a stranded asset.

That fork is why the analyst community keeps circling back to one variable. The speed at which generic semaglutide reaches the world, and the price it lands at, will be governed less by demand than by how quickly SPPS capacity can be built — and how much of the capacity currently dedicated to branded products can be redirected to generic supply. Peptide capacity, not patent expiry, is the throttle. And that is precisely the throttle APAC is racing to grab.

APAC'S RESPONSE

Nowhere is the build-out more consequential than in India, and nowhere in India more than Hyderabad. The country's peptide-CDMO segment starts from a small base — analysts at Primus Partners size it near US$80 million, barely 3% of the roughly US$190 billion global peptide market — but they project it to compound at about 14% a year over five years as patent cliffs and outsourcing tailwinds align. The signal event of 2026 is Neuland Laboratories' commercial peptide facility at its Bonthapally campus near Hyderabad, the first of four planned modules coming online over the summer. Module one adds 6,370 litres of combined SPPS and LPPS reactor capacity — LPPS reactors from 250 to 3,000 litres, SPPS reactors up to 500 litres — and has already secured roughly US$30 million in firm customer commitments, GLP-1 work among them. The site is engineered for phased expansion to 2,000-litre SPPS synthesizers and 5,000-litre LPPS reactors, and plugs into Neuland's existing 1.17 million litres of API capacity across three US FDA-approved plants. It marks the company's move from clinical-stage peptides into commercial-scale supply.

Neuland is not alone. Divi's Laboratories — one of the world's largest API and custom-synthesis houses, and already a supplier of semaglutide building blocks — is expanding its peptide and GLP-1 footprint with commercial volumes expected from late 2027; some analysts model its peptide revenue reaching several hundred million dollars by the end of the decade. Sai Life Sciences opened a dedicated peptide research centre in Hyderabad to chase the same demand. And Granules India bought its way in outright, acquiring Swiss peptide specialist Senn Chemicals in 2025 to graft decades of solid- and liquid-phase know-how onto its formulation and API base. Underwriting the push is policy: the government's production-linked incentive framework and the ₹10,000-crore Biopharma SHAKTI initiative are explicitly aimed at moving India up the value chain from commodity generics into biologics and complex molecules — the category GLP-1 peptides squarely occupy.

The demand-side proof arrived in March 2026, when semaglutide's core patent lapsed in India. Within a day, a wave of domestic launches followed — Sun Pharma, Dr Reddy's, Zydus, Lupin and Mankind among the first movers — and analysts anticipate the market filling with dozens of brands from forty-plus players. Prices that ran to ₹10,000–16,000 a month for the branded product have collapsed toward four figures. Crucially for the manufacturing story, several of these companies are not merely marketers; they intend to make the peptide themselves and export it. Dr Reddy's has flagged generic supply into Canada, Turkey and Brazil, targeting twelve million pens in the first year — a reminder that India supplies roughly a fifth of the world's off-patent medicines and intends to do the same for GLP-1s.

Peptide capacity, not patent expiry, is the throttle on how fast — and how cheaply — the world gets generic GLP-1s.

China, meanwhile, is the region's synthetic-API powerhouse, and by several accounts already leads the world in installed SPPS peptide capacity. WuXi AppTec has steadily expanded its peptide plants in Changzhou and Taixing, adding reactor volume and commercial-scale workshops to an increasingly integrated platform. Aurisco Pharmaceutical has built multi-metric-ton cGMP peptide capacity at its US FDA-inspected Yangzhou site, spanning both synthetic and recombinant routes including commercial-scale semaglutide. Hybio Pharmaceutical and a long tail of domestic players are adding lines behind them, and at least sixteen Chinese companies are developing generic semaglutide ahead of the country's own March 2026 expiry into the world's largest diabetic population. The caveat that recurs in every analyst note is visibility: significant Chinese SPPS capacity exists, but yields, utilisation and real output are hard to verify from the outside — either a hidden reservoir of supply or an overstated one, depending on who is talking.

Korea rounds out the map on the higher-regulatory, higher-margin end. SK pharmteco committed US$260 million to a five-storey, 135,800-square-foot peptide and small-molecule API facility in Sejong, positioning itself for innovator and Western-market work where an FDA-grade quality reputation commands a premium over pure cost.

And then there is the step everyone forgets until it becomes the bottleneck: sterile fill-finish. A GLP-1 API is worthless to a patient until it is aseptically filled into a vial or, more often, a prefilled pen or auto-injector. Through the shortage years the true constraint was frequently not the peptide but the injector devices and the fill-finish lines — a reality the originator underlined when its holding company paid US$16.5 billion for a contract manufacturer largely to lock up fill-finish capacity. APAC's injectable and device-assembly capacity is the less-glamorous half of the same wager, and the region's ability to capture durable CDMO work will depend as much on sterile lines and pen assembly as on synthesis reactors.

FIGURE  ·  PEPTIDE CAPACITY & DEMAND, 2024–2035

Two curves tell the story: rising peptide-API demand against the region's capacity additions — and the route split (fermentation vs SPPS) plotted against the patent-cliff and oral-entry timeline.

▸ Global peptide-API demand (GLP-1):  ~99,000 kg/yr by 2030 (Goldman Sachs). US ~35,000→57,000 kg (2030→35); ex-US/ex-China ~32,000→48,000 kg.

▸ Market value:  GLP-1 class widely put >US$150 bn by 2030; obesity-GLP-1 segment growing ~23% CAGR.

▸ Neuland (Hyderabad):  6,370 L SPPS+LPPS, module 1 of 4, summer 2026; ~US$30 m committed; scalable to 2 kL SPPS / 5 kL LPPS.

▸ Aurisco (Yangzhou):  multi-metric-ton cGMP peptide — synthetic + recombinant.

▸ WuXi AppTec (Changzhou/Taixing):  expanding commercial peptide workshops.

▸ SK pharmteco (Sejong):  US$260 m peptide / small-molecule API facility.

▸ India peptide-CDMO segment:  ~US$80 m today (≈3% of ~US$190 bn global); ~14% CAGR over five years.

▸ The overlay:  fermentation (low cost, high capex, originator) vs SPPS (low capex, harder to scale, generics/CDMOs) — against LOE (Mar 2026) and oral entry (Dec 2025 / May 2026).

Source data verified against Goldman Sachs, Primus Partners, company disclosures and FDA/regulatory filings (2025–2026).

THE DURABILITY RISK

Here is where the tidy curve meets a messier reality, and where the word gamble earns its place in the headline.

The first threat is the patent cliff itself, which cuts both ways. Semaglutide's foundational patent expired on 20 March 2026 across a bloc of major markets — India, China, Brazil, Canada, Turkey and others — that together carry close to half the world's obesity burden. That is the event unlocking APAC generic supply and, with it, much of the demand for regional peptide capacity. But the same cliff is bifurcating the global market. In the United States, the United Kingdom and much of Europe — the highest-value markets by far — layered patents on formulation, dosing and delivery devices extend the originator's exclusivity to 2031 and beyond, in some readings into the early 2040s. So the capacity APAC is building is aimed, for now, at the price-competitive two-thirds of the world, not the premium third. That is a large market. It is also a lower-margin one, and it fills with competitors quickly.

The second threat is more existential, and it is the one that should keep every peptide-capacity investor awake: the pill — and specifically, the non-peptide pill. Two oral GLP-1s reached the US market in quick succession: Novo Nordisk's oral semaglutide (a Wegovy tablet) cleared the FDA in December 2025, and Eli Lilly's orforglipron, branded Foundayo, was approved in May 2026. Oral semaglutide is still a peptide and still needs peptide reactors, so it broadly extends the same demand. Orforglipron does not. It is a small-molecule, non-peptide GLP-1 agonist — conventional chemical synthesis, no SPPS, no metric-ton peptide campaign, and as a pill it sidesteps the sterile fill-finish bottleneck entirely. Lilly has signalled it can scale the product globally without the supply constraints that dogged the injectables, with self-pay pricing starting around US$149 a month. It delivers somewhat less weight loss than the best injectables, but it is dramatically easier and cheaper to make.

When manufacturability becomes the weapon, the molecule that is easiest to make can beat the molecule that works best.

That reframes the entire competition, and it is the reframing that most endangers the APAC bet. When manufacturability becomes a competitive weapon, the molecule that is easiest to make can win share from the molecule that works best — reaching more patients, at lower cost, through a supply chain that never touches a peptide reactor. Every kilogram of demand that migrates from injectable peptide to oral small molecule is a kilogram the region's new SPPS lines do not get to fill. The oral wave does not end peptide manufacturing — injectables will carry the majority of GLP-1 volume for years, and oral peptides keep some of that demand in the peptide column — but it puts a ceiling on the upside the capacity spreadsheets were quietly assuming.

The third threat is compounding, and it runs opposite to the way most assume. In the US, compounded copies were a shortage-era bridge; once the FDA declared the semaglutide and tirzepatide shortages resolved and moved in 2026 to end mass compounding, that gray-market volume began to close off — good for legitimate manufacturers, but a reminder of how quickly regulators can open or shut a channel that moves serious volume. In parts of APAC and other price-sensitive markets, informal and compounded supply remains a wildcard that can undercut the very generic economics the build-out depends on.

The fourth is the longer horizon: as fermentation-based GLP-1s themselves come off patent, a wave of true biosimilars and next-generation molecules — dual and triple agonists like retatrutide and survodutide, amylin combinations — will reshuffle which peptides are even in demand. Capacity tuned for today's semaglutide and tirzepatide has to be flexible enough to make tomorrow's molecules, or it risks being technically obsolete before it is financially amortised.

THE DIFFERENTIATORS — AND WHO CAPTURES THE WORK

Given all that, what actually determines whether an APAC peptide investment pays back? Four things: cost, quality, scale and speed of tech transfer — and the interplay between them decides who wins the outsourced work.

On cost, the region's structural advantage is real but route-dependent. India and China can build and run SPPS lines at a fraction of Western capex and operating cost, decisive for the price-sensitive generic markets they target. But fermentation remains the lowest-cost route at true scale, and the originator's own recombinant capacity keeps a floor under how cheap synthetic generics can go while still turning a profit. The economics reward whoever pairs low-cost synthesis with high, consistent yield — because in SPPS, a few percentage points of yield or purity is the whole margin.

On quality, the field separates. A GLP-1 API destined for regulated markets has to clear US FDA and EMA scrutiny on impurity profiles, and the compounding-safety scares of the shortage years — dosing errors, impurity findings, in extreme cases product with no detectable active ingredient — have made buyers acutely sensitive to provenance. This is where India's FDA-approved plants and Korea's premium positioning earn a premium over opaque, lower-visibility capacity. Quality is also the moat that protects against a pure price race to the bottom.

On scale and tech transfer, the currency is time. The sponsors and generic marketers who need GLP-1 supply are, in analyst shorthand, struggling to secure clinical and commercial manufacturing slots. The CDMO that can take a process, transfer it cleanly, and reach validated commercial output fastest captures the contract — which is exactly why players are integrating LPPS building-block and fragment supply alongside finished API, to shorten and de-risk the chain. Supply-chain resilience has become a selling point in its own right: after the shortages exposed how fragile single-sourced peptide supply chains were — dependent on specialised resins, protected amino acids, coupling reagents and chromatography media — originators and generics alike are deliberately qualifying second and third sources, and APAC is the obvious place to build that redundancy. Diversification of originator supply into the region may prove as important as the region's own generic ambitions.

The honest reading is that the outsourced GLP-1 work will not accrue evenly. It will concentrate among the players who can hold all four attributes at once — cost and quality and scale and transfer speed — and who can stay flexible enough to pivot from semaglutide to tirzepatide to whatever triple agonist dominates in 2030. A great many of the smaller lines going up on the strength of today's demand curve will find themselves competing for a shrinking pool of injectable-peptide volume against exactly the oral molecules that need none of what they built.

THE TAKEAWAY

So: well-timed capacity, or a bet that ages badly? Both — and the split runs down the middle of the fork. The demand is genuine, the largest single manufacturing pull the peptide industry has ever felt, and APAC's cost base, chemistry depth and policy support make it the natural home for a large share of it. For the next several years, injectable peptides will carry most of the volume, the ex-US and ex-China markets will fill with regional supply, and the best-run, FDA-grade CDMOs in India, China and Korea will do very well. That much looks well-timed.

What ages badly is the assumption of a smooth, decade-long curve. The premium markets stay locked behind patents into the 2030s. The oral wave — above all the non-peptide small molecule — puts a hard ceiling on injectable-peptide upside and rewards a supply chain that competes with, rather than uses, the region's new reactors. Compounding rules and biosimilar timelines can reprice the market faster than a plant can be amortised. The region is right that GLP-1 is a peptide-manufacturing story. The gamble is on how long it stays one.

The winners will be the players who treated the build-out not as a bet on GLP-1 volume but as a bet on peptide capability — flexible, high-quality, fast-transferring capacity that can make whatever complex peptide the market wants next. Those firms will look prescient in 2030. The ones who poured concrete purely to chase semaglutide kilograms may find they built for a wave that had already started to break.

(arcilla.fran@biopharmaapac.com)

SOURCES & DATA

Peptide-API demand and route economics: Goldman Sachs (2026). India peptide-CDMO sizing: Primus Partners. Capacity disclosures: Neuland Laboratories, Divi's Laboratories, Sai Life Sciences, Granules India, WuXi AppTec, Aurisco Pharmaceutical, SK pharmteco. Patent expiry and generic entry: IQVIA, company filings, legal analyses (2026). Oral entrants: Eli Lilly, Novo Nordisk, US FDA (Dec 2025 / May 2026). Compounding and fill-finish: US FDA, industry reporting. Figures indicative and to be re-verified at press time.

Disclaimer** Editorial feature by BioPharma APAC (editorially independent). Not investment, financial, legal, or medical advice. Figures are indicative, drawn from third-party and company sources, and unverified; the graphic is illustrative. Trademarks belong to their owners. Current as of publication.